Study of avalglucosidase alfa use during pregnancy
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study collects safety information about avalglucosidase alfa when it’s taken during pregnancy and/or while breastfeeding. If you (or your baby) were exposed to this medicine and consent to be in a pregnancy safety registry, your information may help researchers better understand risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were exposed to avalglucosidase alfa during pregnancy and/or breastfeeding (lactation).
- Your situation involves either you or your baby being included in a safety report/registry process.
- Either an Individual Case Safety Report (ICSR) was already submitted to the sponsor for your exposure, or you can sign informed consent to join.
- You (the pregnant person) must be able to provide informed consent to enroll in the pregnancy sub-registry (if that path applies).
- The study has no stated exclusion rules, so eligibility mainly depends on exposure and consent/registration status.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a registry study that collects information over time from people with Pompe disease. It helps doctors and researchers better understand the condition and how it affects daily life, without testing any new treatments.
This study follows people with Pompe disease over time, even if they are already receiving treatment. It aims to learn more about the disease and how patients are doing over the long run.
This trial provides access to an investigational combination therapy for Pompe disease when standard treatments are not suitable. It aims to help people with Pompe disease who cannot join other clinical studies or are no longer benefiting from current enzyme replacement therapy.
This study follows women with Fabry disease who took the medicine Elfabrio during pregnancy or breastfeeding to see if it is safe for them and their babies. It helps doctors learn more about how this treatment affects mothers and infants.
This study is a long-term follow-up for people who previously finished a trial of the experimental medication S-606001 for late-onset Pompe disease. It tests how safe and effective the drug is over a longer period.
This trial tests an experimental medication called S-606001 for people with late-onset Pompe disease. The goal is to see if it can help improve breathing and walking ability. Participants must not have received enzyme replacement therapy for at least 3 months before starting.
Hear when a new Pompe Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.